Interface Biologics Inc. (“IBI”), a privately held, commercial stage developer of innovative material science technologies for Medtech and Pharmaceutical applications, is pleased to announce the sale of its surface modification business to Evonik, a German based specialty chemical company with revenues in excess of €13 billion in 2018. The Health Care business line of Evonik, a leading supplier of products and services to the pharmaceutical, medical device and nutraceutical industries, will be running the business. The sale does not include IBI’s licensing agreement with Fresenius Medical Care for certain dialysis fields of use.